Setting new standards in information exchange for the pharmaceutical and biotech industry
Conference Forum Presented Immuno-Oncology Panel Discussion During the JP Morgan HealthCare Conference
January 17, 2017
The Conference Forum was delighted to work with a group of leaders in the field of immuno-oncology on a panel focused on Filtering the Hype for the Next Wave of Targets during the JP Morgan Healthcare conference.
Axel Hoos, MD, PhD, SVP Oncology R&D, GSK and Co-Chair, IO360
Ira Mellman, PhD, VP, Cancer Immunology, Genentech
Lindee Goh, Partner, Tapestry Networks
Omid Hamid, MD, Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic
Ramy Ibrahim, MD, VP and Head of R&D, Parker Institute for Cancer Immunotherapy
Key topics addressed included next-generation I/O therapeutics, check point inhibitors, biomarker strategies, coordinating across industry for better approaches to demonstrate value, the future of combinations, the need for high value investigations, challenges with disease modifying medicines, different pathways of costs and coverage for personalized medicine and more. The panel was moderated by Querida Anderson, Editor-in-Chief, BioPharm Insight. After the panel, BioPharm Insight hosted a packed-out reception which took place early evening on January 9th at the Chandran Art Gallery in San Francisco. If you missed the panel, the Conference Forum is presenting the IO360 conference with over 50 leaders in immuno-oncology on February 1-3 in NYC. For more information, click here.
Huge thanks to all the panelists, Kate Woda for organizing the panel and our friends at BioPharm Insights for a great job on the overall event.